Professor Nancy Devlin Director of Research OHE

Slides:



Advertisements
Similar presentations
HEA PTP: M207 Health Economics1 Measurement & Valuation of Health What is health? Why do we need to measure it? How can it be measured? Why do we need.
Advertisements

Measuring outcomes Emma Frew October Measuring outcomes Learning objectives By the end of the session students should be able to – Explain how different.
Emma Frew Introduction to health economics, MSc HEHP, October 2012 Outcomes: part II.
Technology Appraisal of Medical Devices at NICE – Methods and Practice Mark Sculpher Professor of Health Economics Centre for Health Economics University.
1 Does it make a difference for the patient? Survival & Quality of life  Jan J. v. Busschbach, Ph.D.  Erasmus MC Institute for Medical Psychology and.
The role of economic modelling – a brief introduction Francis Ruiz NICE International © NICE 2014.
Utility Assessment HINF Medical Methodologies Session 4.
The Importance of Decision Analytic Modelling in Evaluating Health Care Interventions Mark Sculpher Professor of Health Economics Centre for Health Economics.
Journal Club Alcohol and Health: Current Evidence March-April 2006.
Decision Analysis as a Basis for Estimating Cost- Effectiveness: The Experience of the National Institute for Health and Clinical Excellence in the UK.
25 Sept 07 FF8 - Discrete Choice Data Introduction Tony O’Hagan.
By Dr. Ahmed Mostafa Assist. Prof. of anesthesia & I.C.U. Evidence-based medicine.
Sample Size Determination
QUALITY OF LIFE ASSESSMENT IN PEOPLE LIVING WITH HIV/AIDS Antonieta Medina Lara HIV/AIDS and STI Knowledge Programme Liverpool School of Tropical Medicine.
Measuring and valuing health outcome Montarat Thavorncharoensap, Ph.D. 1: Faculty of Pharmacy, Mahidol University 2. HITAP, Thailand.
MAPPING THE DIABETES HEALTH PROFILE (DHP-18) ONTO THE EQ-5D AND SF-6D GENERIC PREFERENCE BASED MEASURES OF HEALTH Brendan Mulhern 1, Keith Meadows 2, Donna.
1 EQ-5D, HUI and SF-36 Of the shelf instruments…..
Sampling. Concerns 1)Representativeness of the Sample: Does the sample accurately portray the population from which it is drawn 2)Time and Change: Was.
Economic evaluation of health programmes Department of Epidemiology, Biostatistics and Occupational Health Class no. 11: Cost-utility analysis – Part 4.
1 OECD Handbook on Measuring Volume Output of Education and Health Chapter 3: Health Sandra Hopkins OECD Health Division June 2007.
Cost-Effectiveness Thresholds Professor of Health Economics
#1 STATISTICS 542 Intro to Clinical Trials Quality of Life Assessment.
Basic Economic Analysis David Epstein, Centre for Health Economics, York.
Validation / citations. Validation u Expert review of model structure u Expert review of basic code implementation u Reproduce original inputs u Correctly.
1 EQ-5D, HUI and SF-36 Of the shelf instruments…..
Economic evaluation of health programmes Department of Epidemiology, Biostatistics and Occupational Health Class no. 23: Nov 17, 2008.
1 Health outcome valuation study in Thailand Sirinart Tongsiri Research degree student Health Services Research Unit, Public Health & Policy Department.
Medical Statistics as a science
1 Session 6 Minimally Important Differences Dave Cella Dennis Revicki Jeff Sloan David Feeny Ron Hays.
Using State Tests to Measure Student Achievement in Large-Scale Randomized Experiments IES Research Conference June 28 th, 2010 Marie-Andrée Somers (Presenter)
CoRPS London 26 & 27 October 2010 Center of Research on Psychology in Somatic diseases Understanding PRO in hematological disorders: Do we have a consensus?
PRAGMATIC Study Designs: Elderly Cancer Trials
Multivariate Analysis - Introduction. What is Multivariate Analysis? The expression multivariate analysis is used to describe analyses of data that have.
Intro to Qualitative Research Scientific Practice.
Professor Nancy J. Devlin Office of Health Economics Royal Statistical Society June 18 th 2015 Measuring and ‘valuing’ patient reported health.
Some epidemiological principles and methods
Professor David Parkin King’s College London
for Overall Prognosis Workshop Cochrane Colloquium, Seoul
HEALTH ECONOMICS BASICS
Types of Research Studies Architecture of Clinical Research
Evidence-based Medicine
Patient Involvement in the HTA Decision Making Process
WHO The World Health Survey General Introduction
Variation in health state preferences across local and international populations: East doesn’t meet West CADTH symposium Panel Session April 12, 2016.
Quality of Life Assessment
Patient Baseline Assessment
Multivariate Analysis - Introduction
Clinical Studies Continuum
Confidence Intervals and p-values
How useful is a reminder system in collection of follow-up quality of life data in clinical trials? Dr Shona Fielding.
Measurement Wu Gong, MS, MD
Challenges of statistical analysis in surgical trials
Chapter 7 The Hierarchy of Evidence
Critical Reading of Clinical Study Results
S1316 analysis details Garnet Anderson Katie Arnold
11/20/2018 Study Types.
A Review of Methods used to Quantify Effect Sizes in Clinical Trials
Evaluating Impacts: An Overview of Quantitative Methods
How to apply successfully to the NIHR HTA Board?
EAST GRADE course 2019 Introduction to Meta-Analysis
Inequalities in Health
Assessing value for money: principles, methods and issues
Expert Group on Quality of Life Indicators
Sample Sizes for IE Power Calculations.
Regulatory Perspective of the Use of EHRs in RCTs
Multivariate Analysis - Introduction
Measuring outcomes Emma Frew October 2012.
Elicitation methods Health care demands exceed resource supply
Presentation Developed for the Academy of Managed Care Pharmacy
Patient-reported Outcome Measures
Presentation transcript:

The role of patient reported outcome (PRO) data in HTA: issues in measuring and valuing health Professor Nancy Devlin Director of Research OHE PSI conference, May 16th 2017

Content Patient reported outcomes (PROs) – what do they measure? Why are they important? Descriptive systems and profile data Analysing profile data 3. Patients’ assessments of overall health 4. Scoring and values/utilities Sources/properties of values; implications for statistical analysis of utilities 5. Differences between the 3L and 5L; implications for HTA And I will end with some concluding remarks

Much of what I will say today is drawn from these papers

1.PROs: what do they measure? The goal of most health care is to improve patients’ health Patients arguably the best judge of how they feel “The use of PRO instruments is part of a general movement toward the idea that the patient, properly queried, is the best source of information about how he or she feels” (FDA 2006) PROs: aim to capture patients’ subjective account of their own health in a structured way. Psychometric properties: validity; reliability PRO data a useful complement (not substitute) for clinical endpoints.

How is health described? Types of PROs How is health described? How is health summarised? Generic Condition-specific Scores Eg. SF-36 Eg. Oxford Hip Score, Oxford Knees Score (literally thousands of such PROs exist) Values/utilities Eg. EQ-5D HUI SF-6D AQOL 15D Mapping to preference based measures (various methods) Some condition specific instruments accompanied by value sets eg. EORTC-8D, derived from the EORTC QLQ-C30 for use in patients with cancer Notes: - generic and condition specific instruments have a different role: generic allows comparisons across disease areas (to weigh up benefit gained with benefit foregone elsewhere); condition-specific provide rich data on specific disease/health problem. Common to map from disease specific to preference based instrument (various methods; map to utilities or map to generic descriptive system) but preferable to collect generic data Best practise: collect both generic and condition specific.

Uses of PROs Clinical trials Observational studies Population health surveys Routine collection in health service delivery, eg. ‘PROMs’ in English NHS UK private health care sector (PHIN) Alberta Health Services, Canada New Zealand Southern Cross.

EQ-5D descriptive system and profile One of the most common generic, preference-based PROs. Available 5 level (shown here) or 3L (used since 1990s; recommended by NICE)

EQ-VAS: Patients’ overall assessment of their health

Utilities Single number summaries of how good or bad each health state is Anchored at 1= full health, 0 = dead, < 0 worse than dead (as required by QALYs) Based on stated preferences of general public considering hypothetical states With exceptions eg. Sweden’s TLV prefers patient’s values Both could be argued to be relevant: “health economic guidelines could require analysis of benefit in terms of QALYs based on both patient and general public preferences” (Versteegh & Brouwer 2017)

Utility/happiness Quality of life What EQ-5D and other PROs measure is nested within broader concepts of QoL and utility. Conceptually, the borders between HR-QoL and QoL and between QoL and utility are not precisely defined. Quality of life Health-related quality of life Health status EQ-5D profile captures specific aspects of HR-QoL EQ-VAS (a ‘feeling thermometer’) which captures the patients’ overall assessment of how good or bad their health is; Utilities (values) which capture the general public’s affective forecasts of utility in those states Increasing interest in broader concepts: social care outcomes; subjective wellbeing and ‘happiness’

Profiles: simple descriptive analysis Nature of profiles observed + value set characteristics drive observed distribution of utilities eg. in these 3L data, no level 3 observed on mobility ‘N3’ term on 3L utilities important characteristic of utility This sort of analysis aggregates data by dimensions/levels. It doesn’t show how dimensions/levels combine on a within-respondent basis

Pareto classification of health change Comparing a patient’s PRO profile at any 2 points in time: The same Better on at least 1 dimension, no worse on others = improvement Worse on at least 1 dimension, and no better on others = worsening Better on some dimensions, worse on others = mixed

What is the EQ-VAS measuring?

4. Scores and utilities Act to weight the levels/dimensions in profiles so they can be aggregated into a single number Preference based (values/utilities) or non- preference based (scores) Utilities: 1= full health, 0 = dead, < 0 worse than dead Neither are ‘neutral’ – there is no objective way of aggregating profile data Which value set is used introduces an exogenous source of variance, and can bias statistical inference. The paper where we show this point is: Parkin D, Devlin N, Rice N. (2010) Statistical analysis of EQ-5D profiles: does the use of value sets bias inference? Medical Decision Making 2010; 30:556-565

What causes the distribution of observed utilities? The distribution of utilities is caused both by the properties of the value set and by the properties of the profile data Profile data are often clustered, and highly ‘concentrated’ ie a surprisingly small number of profiles account for the majority of observations. This is important to know since the characteristics of the profile data at baseline will determine what improvements (specific dimensions/levels) are possible. For more on this, see: Parkin Devlin Feng (2016) What determines the shape of an EQ-5D Index distribution? Medical Decision Making. http://journals.sagepub.com/doi/abs/10.1177/0272989X16645581

5L value set Both papers free to download: www.ohe.org

EQ-5D-5L valuation protocol

Comparing 3L and 5L value sets UK 3L: Dolan 1997 UK ‘Crosswalk’ van Hout et al 2013 England 5L: Devlin et al 2016 The 3L value set, and the crosswalk value set which drew off the same data, had what we call a bimodal property. The 5L value set does not have that property.

Comparison with 3L and ‘crosswalk’   5L value set Crosswalk value set 3L value set % health states worse than dead 5.1% (159 out of 3,125) 26.7% (833 out of 3,125) 34.6% (84 out of 243) Preferences regarding dimensions (ordered from most to least important in terms of level 5 weight) Pain/Discomfort Anxiety/Depression Mobility Self-care Usual Activities Value of 55555 (33333) -0.285 -0.594 Value of 11112* 0.922 0.879 0.848 Value of 11121* 0.937 0.837 0.796 Value of 11211* 0.950 0.906 0.883 Value of 12111* 0.846 0.815 Value of 21111* 0.942 0.877 0.850 Minimum value Maximum value 1.000

Implications of the results The EQ-5D-5L value set for England has a lower range of values than the current UK EQ-5D-3L value set Proportion of states with negative values is considerably lower Implies that treatments for very severe conditions generate smaller gains than is currently assumed e.g. interventions that reduce the level of anxiety/depression from extreme to severe Treatments seeking to alleviate pain/discomfort and anxiety/depression are highly valued and most likely to be prioritised Mobility is less influential than before Life-extending treatments may generate larger gains than is currently assumed

Concluding remarks PRO data are often under-analysed. Be aware of the nature of the underlying profile data in your sample Look at patients’ EQ-VAS data Be aware of the characteristics of the value set (or scoring system) used to summarise profiles – results may be affected by it (sensitivity analysis) Understand the normative issues determining choice of value set, and whether relevant to your study (eg if not estimating QALYs, utilities may not be the most relevant)